The American Hospital Association has been working to educate policymakers and the public about the significant challenges facing our field. The AHA in 2024 will work with Congress, the Administration, the regulatory agencies, the courts and others to positively influence the public policy…
- Advocacy & Public Policy
- Novel Coronavirus (SARS-CoV-2/COVID-19)
- Access & Health Coverage
- Access to Care in Vulnerable Communities
- Access to Behavioral Health
- Disparities/Equity of Care
- Reducing Healthcare Disparities
- Quality & Patient Safety
- Making Healthcare More Affordable
- Advancing Best Practices for Hospitals & Health Systems
Paxlovid may no longer be distributed with an emergency use label after March 8, the Food and Drug Administration announced.
The Home Test to Treat program now offers free testing, telehealth and treatment for both COVID-19 and flu to eligible adults nationwide, the National Institutes of Health announced.
The Food and Drug Administration Nov. 9 cleared for marketing the Flowflex COVID-19 Antigen Home Test, the first COVID-19 antigen test and second COVID-19 at-home test to successfully complete traditional premarket review.
Fewer than one in four health care professionals working in acute care hospitals and nursing homes were up to date with COVID-19 vaccination during the 2022-23 flu season, defined as receiving a bivalent booster dose or completing a primary series in the previous two months, and fewer than half of…
The Department of Health and Human Services Oct. 27 urged Merck and Pfizer to work with private insurers to maintain access to their COVID-19 oral antiviral medications as they transition from federal to commercial distribution, beginning Nov. 1.
The Food and Drug Administration recently extended to 30 months the shelf life for certain lots of Gohibic (vilobelimab), authorized for emergency use to treat COVID-19 in certain hospitalized adults.
A peer-to-peer community of health care executives dedicated to helping hospitals and health systems recover, rebuild and reimagine health care in response to COVID-19.
The Department of Health and Human Services’ Administration for Strategic Preparedness and Response yesterday awarded $600 million for 12 domestic COVID-19 test manufacturers to expand capacity.